The worldwide trend of using botanical drugs and strategies for developing global drugs

  • Ahn, Kyungseop (Natural Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology)
  • 투고 : 2016.12.20
  • 발행 : 2017.03.31


Natural product drugs, or botanical drugs, are drugs composed of natural substances which have constituents with healthenhancing or medicinal activities. In Korea, government-led projects brought attention to botanical drugs invigorating domestic botanical drug industry. Foreign markets, as well, are growing bigger as the significance of botanical drugs stood out. To follow along with the tendency, Korea puts a lot of effort on developing botanical drugs suitable for global market. However, standards for approving drug sales vary by countries. And also, thorough standardization, certification, clinical studies and data of these will be required as well as data confirming safety and effectiveness. Meanwhile, as an international exchange in botanical drug market continues, the importance of plant resources was emphasized. Thus countries' ownership of domestic natural resources became vital. Not only establishing a systematic method to secure domestic plant resources, but also cooperation with other countries on sharing natural resources is essential to procure natural resources effectively. Korea started to show visible results with botanical drugs, and asthma/COPD treatment made out of speedwell is one example. Sufficient investment and government's active support for basic infrastructure for global botanical drugs will bring Korea to much higher level of botanical drug development.


연구 과제 주관 기관 : Korea Research Institute of Bioscience and Biotechnology


  1. Blumenthal M (2006) FDA approves special green tea extract as a new topical drug for genital warts. HerbalGram (Austin, Tex.) November 9
  2. Liscinsky M (2012) FDA approves the first anti-diarrheal drug for HIV/AIDS patients. US Food and Drug Administration (Silver Spring, MD) December 31
  3. American Botanical Council (2013) FDA approves CRO Elem eras first-several botanical drug. American Botanical Council (Austin,TX) January 2
  4. Biotech Policy Research Center (2012) White paper on Research and Development in the Korean Pharmaceutical Industry. Biotech Policy Research Center 2012
  5. Report on the Bioproducts Market and Trends in Biotechnology Development (2010) Ministry of Knowledge Economy/Korea Evaluation Institute of Industrial Technology/Korea Biotechnology Industry Organization
  6. Biotech Policy Research Center (2012) Trends in Research and Development on Novel Botanical Medicine. Biotech Policy Research Center
  7. US Food and Drug Administration (2013) Investigational New Drug application. US Food and Drug Administration September
  8. US Food and Drug Administration (2013) New Drug Application. US Food and Drug Administration website April 30
  9. Morphy R and Rankovic Z (2009) Designing multiple legends-medicinal chemistry strategies and challenges. Curr Pharm Des 15, 587-600
  10. Zimmermann GR, Lehar J and Keith CT (2007) Multitarget therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12, 34-42
  11. Frantz S (2005) Drug discovery: playing dirty. Nature 437, 942-943
  12. Parwardhan B and Mashelkar RA (2009) Traditional medicine-inspired approaches to drug discovery: can Ayurveda show the way forward? Drug Discov Today 14, 804-811
  13. Patwardhan B, Vaidya ADB, Chorghade M and Joshi SP (2008) Reverse pharmacology and systems approaches for drug discovery and development, Curr Bioact Compd 4, 1-11
  14. Korea Biotechnology Industry Organization (2014) Seminar Presentation on the Strategy for Global Clinical Expansion of New Drug Development, Korea Biotechnology Industry Organization
  15. Quality Standardization Based Botanical Drug Development Center (2013) Symposium Presentation on the Botanical Drug Material Development and Overseas Expansion Strategies. Quality Standardization Based Botanical Drug Development Center
  16. Lee K (2014) Countermeasures by the Bio- and Pharmaceutical Industries against the Implementation of the Nagoya Protocol Regarding Access and Benefit-sharing. Gyeonggi Bio Insight
  17. Oh S (2011) Status of Botanical Medicine Based on Plant-derivative Materials. Bioin Special
  18. Son M (2014) Strategies and Case Studies of Research and Development of Novel Botanical Medicine by DongaST. Gyeonggi Bio Insight

피인용 문헌

  1. Antioxidant Potential of Selected Korean Edible Plant Extracts vol.2017, pp.2314-6141, 2017,
  2. Effects of the Extracts from Fruit and Stem of Camellia japonica on Induced Pluripotency and Wound Healing vol.7, pp.11, 2018,
  3. Supplementation of Abelmoschus manihot Ameliorates Diabetic Nephropathy and Hepatic Steatosis by Activating Autophagy in Mice vol.10, pp.11, 2018,